Looking at a Drink to Help Manage Chemotherapy Side Effects for Colon Cancer

Recruiting · Phase 2 · Metastatic Colon Carcinoma and related conditions · New Jersey

Check if I qualify View on ClinicalTrials.gov

About this trial

This trial looks at a product called NBT-NM108 that may help patients with colon cancer. It focuses on whether this drink can reduce diarrhea caused by chemotherapy. Diarrhea is a common issue with the medicine irinotecan, which is used to treat colon cancer. The hope is that NBT-NM108 can make it easier for patients to handle their treatment by improving gut health and reducing diarrhea symptoms.

The trial's ID number is NCT05296681. This is a Phase 2 trial, which means it is looking at how well the treatment works and its safety. It is regulated by the FDA and aims to include about 42 participants.

Who can join

Men and women aged 18 and older can join. They must have colon cancer that has spread and be starting a specific type of chemotherapy. Some health conditions may prevent someone from joining, like severe diarrhea or certain gastrointestinal diseases. The trial team will confirm who is eligible to participate.

Conditions

Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants are randomly placed into two groups. One group will drink NBT-NM108 four times a day for 56 days, starting before chemotherapy. The other group will receive standard chemotherapy without the special drink. Everyone will receive irinotecan-based chemotherapy as part of their treatment.